Research from Intermountain Health in Salt Lake City highlights the potential of genetic screening to identify individuals with familial hypercholesterolemia (FH), enabling them to receive treatment that could prevent heart attacks, strokes, and fatalities.
FH, an inherited condition affecting approximately 1 in 250 people, often manifests without symptoms until a heart attack occurs. For those with FH, conventional methods like dietary or behavioral changes cannot effectively lower “bad” cholesterol levels due to genetic factors, necessitating targeted medication therapy.
Stacey Knight, PhD, a cardiovascular and genetic epidemiologist at Intermountain Health, emphasized the importance of genetic testing for individuals with unexplained high cholesterol, as it allows for aggressive treatment to reduce the risk of major heart events.
The research findings were presented at the American Heart Association’s Scientific Sessions 2023 in Philadelphia.
News in Same Category
Can Navitoclax be a Lower Back Pain Breakthrough?
Tobacco-Related Cancers Claim 1.3 Million Lives Yearly in India and Six Other Countries
Rising Type 2 Diabetes Cases in Children Linked to Changing Lifestyles
Israeli Military’s Attacks on Gaza Healthcare Spark Global Outcry
Tragic Measles Death in Malappuram Highlights Urgent Vaccination Need
Study Links Human Behavior to COVID-19 Evolution
Soda Intake in Youth Linked to Future Alcohol Use and Cognitive Effects
Raw Meat Diet Increases Risk of Antibiotic-Resistant E. coli in Dogs
Combination Therapy Shows Promise for Pediatric Glioma Treatment in BRAF-Mutated Cases
AIIMS Delhi Adds 63 Free Drugs for Low-Income Patients
